Correlation between the pharmacokinetics of oxindanac and inhibition of serum thromboxane B2 in calves.
The pharmacokinetics and pharmacodynamics of the non-steroidal antiinflammatory drug, oxindanac, were assessed simultaneously in calves after intravenous (i.v.) administration at dose rates of 0.5, 1, 2, 4 and 8 mg/kg. Plasma pharmacokinetic data were fitted to either two or three compartment open models. The elimination t1/2 was constant in the dose range 0.5 to 4 mg/kg (20.2-22.8 h) and shorter at 8 mg/kg (14.7 h). The pharmacodynamics of oxindanac were assessed by its inhibition of serum TxB2, an index of platelet cyclo-oxygenase activity. Plots of total plasma oxindanac concentration vs. inhibition of serum TxB2 fitted in all cases a sigmoidal Emax equation. There were no significant differences in the estimates for ED50 (1.6-1.9 micrograms/ml), Hill constant (1.3-2.7) or Emax between the doses used in the in vivo studies or when blood was spiked with oxindanac in vitro. Plots of inhibition of serum TxB2 vs. time were prepared from the pharmacokinetic model equations in each calf in combination with a single sigmoidal Emax plot generated in vitro. These data were not significantly different from the results produced in vivo. It is concluded that oxindanac causes reversible inhibition of platelet cyclo-oxygenase in calves. Its inhibition of serum TxB2 can be predicted from total plasma drug concentration, as described by a multicompartmental model, and sigmoidal Emax enzyme kinetics. It was not necessary to take into account factors such as drug equilibration between plasma and its target site, free vs. total drug concentration or chirality. This simple model may be useful for predicting the pharmacodynamics of oxindanac in other species.
King
J N
JN
Ciba-Geigy Animal Health, Centre de Recherches Agricoles, St. Aubin, Switzerland.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics* / Q000494:pharmacology; D002417:Cattle / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid / Q000662:veterinary; D006207:Half-Life; D007192:Indenes / Q000493:pharmacokinetics* / Q000494:pharmacology*; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects; D013929:Thromboxane B2 / Q000037:antagonists & inhibitors* / Q000097:blood
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007192:Indenes; D013929:Thromboxane B2; D011451:Prostaglandin-Endoperoxide Synthases; C039724:oxindanac